Nantahala Capital Management, LLC
Position in NBIX — Neurocrine Biosciences Inc
CIK 1472322
New Canaan, CT
Position in NBIX
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in NBIX
reported options exposure · as of Jun 30, 2026CallValue
$33,708,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Nantahala Capital Management, LLC holds $169,874,929 across 9 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ETON |
Eton Pharmaceuticals, Inc.
|
1,175,951 | $42,569,426 | |
| 2 | AMRX |
Amneal Pharmaceuticals, Inc.
|
2,268,751 | $39,272,079 | |
| 3 | EOLS |
Evolus, Inc.
|
5,602,021 | $38,878,025 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,901,160 | $19,011,600 | |
| 5 | ADCT |
ADC Therapeutics SA
|
12,326,184 | $13,189,016 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
486,684 | $8,740,844 | |
| 7 | TLPH |
Talphera, Inc.
|
3,492,519 | $3,597,294 | |
| 8 | AYTU |
Aytu Biopharma, Inc
|
1,086,812 | $2,336,645 |
All Filings in NBIX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $33,708,000 | 200,000 | Call | Sole | 2026-08-19 | |
| No filing history on record for this holder in this stock. | ||||||